相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook et al.
CLINICAL CANCER RESEARCH (2020)
High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification
Chi Young Ok et al.
PATHOLOGY (2020)
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
Thomas E. C. Cummin et al.
BLOOD ADVANCES (2020)
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D. Zelenetz et al.
BLOOD (2019)
MYC in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities
Andrea Bisso et al.
IMMUNOLOGICAL REVIEWS (2019)
The role of aurora A and polo-like kinases in high-risk lymphomas
Carlos Murga-Zamalloa et al.
BLOOD ADVANCES (2019)
Reactivating TP53 signaling by the novel MDM2 inhibitor DS3032b as a therapeutic option for high-risk neuroblastoma
Viktor Arnhold et al.
ONCOTARGET (2018)
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
Wei Liu et al.
ONCOTARGET (2018)
41OA phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
K A Blum et al.
ANNALS OF ONCOLOGY (2018)
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
Jo Ishizawa et al.
CANCER RESEARCH (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
A. Esteve-Arenys et al.
ONCOGENE (2018)
Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
Amita Patnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mutational processes shape the landscape of TP53 mutations in human cancer
Andrew O. Giacomelli et al.
NATURE GENETICS (2018)
Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov et al.
NATURE REVIEWS CANCER (2018)
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma
Xuan J. Wang et al.
MODERN PATHOLOGY (2017)
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
Alex F. Herrera et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma
Jinfen Wang et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma
Lan V. Pham et al.
ONCOTARGET (2016)
Functional Significance of Aurora Kinases-p53 Protein Family interactions in Cancer
Kaori Sasai et al.
FRONTIERS IN ONCOLOGY (2016)
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis
Christina Howlett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas A Retrospective Cohort Study
Ana-Iris Schiefer et al.
MEDICINE (2015)
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Zijun Y. Xu-Monette et al.
MODERN PATHOLOGY (2015)
TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations
Niklas Gebauer et al.
LEUKEMIA & LYMPHOMA (2015)
The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit
Alexandra Clipson et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2015)
p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression A Single Institutional Clinicopathologic Study
Yi Xie et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Double hit lymphoma: the MD Anderson Cancer Center clinical experience
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Alexandar Tzankov et al.
MODERN PATHOLOGY (2014)
MYC and the Control of Apoptosis
Steven B. McMahon
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
Zijun Y. Xu-Monette et al.
BLOOD (2013)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
Wendy Cuccuini et al.
BLOOD (2012)
p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation
Chun-Chi Wu et al.
CELL CYCLE (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
C. Visco et al.
LEUKEMIA (2012)
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state
Juergen den Hollander et al.
BLOOD (2010)
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
Kerry J. Savage et al.
BLOOD (2009)
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma:: an international collaborative study
Ken H. Young et al.
BLOOD (2008)
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma
Ken H. Young et al.
BLOOD (2007)
Aurora-kinase inhibitors as anticancer agents
N Keen et al.
NATURE REVIEWS CANCER (2004)
分享论文
